Purchase this article with an account.
Marina Mesquida, Faye Drawnel, Philippa J. Lait, David A. Copland, Madeleine L. Stimpson, Victor Llorenç, Maite Sainz de la Maza, Alfredo Adan, Gabriella Widmer, Pamela Strassburger, Sascha Fauser, Andrew D. Dick, Richard W. J. Lee, Blanca Molins; Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood–Retinal Barrier Integrity In Vitro. Trans. Vis. Sci. Tech. 2019;8(5):32. doi: https://doi.org/10.1167/tvst.8.5.32.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Macular edema (ME) is a leading cause of visual loss in a range of retinal diseases and despite the use of antivascular endothelial growth factor (anti-VEGF) agents, its successful treatment remains a major clinical challenge. Based on the indirect clinical evidence that interleukin-6 (IL-6) is a key additional candidate mediator of ME, we interrogated the effect of IL-6 on blood–retinal barrier (BRB) integrity in vitro.
Human retinal pigment epithelial cell (ARPE-19) and human retinal microvascular endothelial cell (HRMEC) monolayers were used to mimic the outer and inner BRB, respectively. Their paracellular permeability was assessed by measuring the passive permeation of 40 kDa fluorescein isothiocyanate (FITC)-dextran across confluent cells in the presence of IL-6. Transendothelial/epithelial electrical resistance (TEER) then was measured and the distribution of the tight junction protein ZO-1 was assessed by immunofluorescence using confocal microscopy.
Treatment with IL-6 for 48 hours significantly increased the diffusion rate of FITC-dextran, decreased TEER, and disrupted the distribution of ZO-1 in ARPE-19 cells, which constitutively express the IL-6 transmembrane receptor, and this was reversed with IL-6R blockade. In contrast, IL-6 did not affect the paracellular permeability, TEER, or ZO-1 distribution in HRMECs.
These in vitro data support the hypothesis that IL-6 reversibly disrupts the integrity of ARPE-19 cells, but it does not affect HRMECs.
IL-6 is a candidate therapeutic target in the treatment of outer BRB driven ME.
This PDF is available to Subscribers Only